Investing.com — Ose Immunotherapeutics stock dropped 4.25% following an announcement that the company has amended its agreement with AbbVie (NYSE:ABBV) for their immunotherapy development partnership …
Ose Immunotherapeutics stock falls after AbbVie deal amendment
view original post